Gerald L. Andriole, Jr., MD

Prostatype Genomics

St. Louis, Missouri

Gerald L. Andriole, Jr., MD, is the Chief Medical Officer of Prostatype Genomics AB in St. Louis, Missouri. Dr. Andriole is an internationally recognized key opinion leader in urology with a significant focus on prostate cancer. His research and clinical experience, much of which focuses on genomic testing, allows him to continue to positively impact the quality of care and outcomes for patients diagnosed with prostate cancer.

Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester in New York. Dr. Andriole then completed his residency in Urology at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts. Dr. Andriole went on to complete a fellowship in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland.

Dr. Andriole has over 40 years of consistent contributions in the areas of prostate cancer screening and prevention research as well as benign prostatic hyperplasia. He has contributed over 450 peer-reviewed publications. He chaired the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, the Steering Committee of the international REDUCE (reduction by dutasteride of prostate cancer events) Chemoprevention Trial, and the Prostate Committee of the Society of Urologic Oncology Clinical Trials Consortium. He is a member of numerous societies and associations, including the American Urological Association, the Academy of Master Surgical Educators of the American College of Surgeons, the American Surgical Association, the American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons. His work has been recognized with a number of awards, including the Outstanding Achievement Award from the Urologic Oncology Branch of the National Cancer Institute, the Distinguished Clinician Award from Washington University, the Alumni Award from Jefferson Medical College, and the Williams Award for Prostate Cancer Research Excellence from the American Urological Association’s Urology Care Foundation.

Talks by Gerald L. Andriole, Jr., MD

5-Alpha Reductase Inhibitors Increase the Risk of Aggressive Prostate Cancer: Fact or Myth

Gerald L. Andriole, Jr., MD | Feb 2025

Gerald L. Andriole, Jr., MD, challenges misconceptions about 5-ARIs in urology, focusing on their role in prostate cancer.

MicroUltrasound of the Prostate

Gerald L. Andriole, Jr., MD | Feb 2025

Gerald L. Andriole, Jr., MD, discusses the evolving role of micro-ultrasound in prostate cancer detection.

Micro Ultrasound and MRI of the Prostate

Gerald L. Andriole, Jr., MD | Oct 2024

Dr. Gerald L. Andriole, Jr., MD, analyzes the evolving role of micro-ultrasound and MRI in the diagnosis and management of prostate cancer and discusses the advancements in imaging technologies that have significantly improved the accuracy of prostate cancer detection.

In this 13-minute talk, Dr. Andriole begins by examining the limitations of utilizing single imaging techniques, particularly in detecting small, clinically significant prostate tumors. Dr. Andriole explores the complementary role of micro-ultrasound and multiparametric MRI (mpMRI) in prostate cancer imaging. This combination of micro-ultrasound and MRI, he notes, enhances the accuracy of prostate cancer diagnosis.

Dr. Andriole also highlights the clinical implications of these imaging modalities and their potential to reduce the need for unnecessary biopsies and more effectively guide active surveillance strategies. He discusses the ongoing research and developments to integrate these technologies into routine clinical practice.

Micro Ultrasound and MRI of the Prostate

Gerald L. Andriole, Jr., MD | Sep 2024

Gerald L. Andriole, Jr., MD, is the global Chief Medical Officer at Prostatype Genomics. He previously was Professor and Director of Urology in the National Capital Region at the Brady Urologic Institute at Johns Hopkins University. Throughout this 13-minute presentation, Dr. Andriole underscores the importance of staying abreast of technological advancements in urology, as they can transform prostate cancer care.

Prostate Cancer Screening Update

Gerald L. Andriole, Jr., MD | Jun 2024

Gerald L. Andriole, Jr., MD, provides guidance on how urologists can effectively streamline their processes for prostate cancer screening. In his presentation, he discusses five supplemental areas where urologists can improve prostate cancer screening:

Identification of Above Average Risk Patients
Simplification of PSA Guidance for Patients and PCPs
Early Identification of Clinically Significant Prostate Cancer
Reduction of Unnecessary Initial and Repeated Biopsies
Enhanced Risk Stratification

For each area, Dr. Andriole outlines the current standard practice and suggests methods for improvement. To support the suggested methods, he presents data illustrating the method’s outcome for patients and practitioners.